Ian C. Mortimer's most recent trade in Xenon Pharmaceuticals Inc was a trade of 275,000 Share Option (Right to Buy) done . Disclosure was reported to the exchange on March 12, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Xenon Pharmaceuticals Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2025 | 275,000 | 275,000 | - | - | Share Option (Right to Buy) | |
| Xenon Pharmaceuticals Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2025 | 50,000 | 50,000 | - | - | Restricted Share Units | |
| Xenon Pharmaceuticals Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.76 per share. | 23 Jan 2025 | 22,468 | 53,770 (0%) | 0% | 17.8 | 399,032 | Common Shares |
| Xenon Pharmaceuticals Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 40.20 per share. | 23 Jan 2025 | 22,468 | 31,302 (0%) | 0% | 40.2 | 903,214 | Common Shares |
| Xenon Pharmaceuticals Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2025 | 22,468 | 16,315 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharmaceuticals Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2025 | 16,315 | 0 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharmaceuticals Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.76 per share. | 23 Jan 2025 | 16,217 | 47,519 (0%) | 0% | 17.8 | 288,014 | Common Shares |
| Xenon Pharmaceuticals Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 40.08 per share. | 23 Jan 2025 | 16,217 | 31,302 (0%) | 0% | 40.1 | 649,977 | Common Shares |
| Xenon Pharmaceuticals Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2025 | 16,217 | 38,783 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharmaceuticals Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.76 per share. | 23 Jan 2025 | 15,166 | 46,468 (0%) | 0% | 17.8 | 269,348 | Common Shares |
| Xenon Pharmaceuticals Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 40.46 per share. | 23 Jan 2025 | 15,166 | 31,302 (0%) | 0% | 40.5 | 613,616 | Common Shares |
| Xenon Pharmaceuticals Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.76 per share. | 23 Jan 2025 | 1,149 | 32,451 (0%) | 0% | 17.8 | 20,406 | Common Shares |
| Xenon Pharmaceuticals Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 41.07 per share. | 23 Jan 2025 | 1,149 | 31,302 (0%) | 0% | 41.1 | 47,189 | Common Shares |
| Xenon Pharmaceuticals Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2024 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharmaceuticals Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 May 2023 | 42,592 | 0 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharmaceuticals Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.44 per share. | 24 May 2023 | 42,592 | 48,592 (0%) | 0% | 9.4 | 402,068 | Common Shares |
| Xenon Pharmaceuticals Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 May 2023 | 20,576 | 0 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharmaceuticals Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.85 per share. | 24 May 2023 | 20,576 | 44,789 (0%) | 0% | 9.9 | 202,674 | Common Shares |
| Xenon Pharmaceuticals Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 41.44 per share. | 24 May 2023 | 17,069 | 24,213 (0%) | 0% | 41.4 | 707,339 | Common Shares |
| Xenon Pharmaceuticals Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 41.37 per share. | 24 May 2023 | 13,179 | 27,708 (0%) | 0% | 41.4 | 545,215 | Common Shares |
| Xenon Pharmaceuticals Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 41.84 per share. | 24 May 2023 | 7,310 | 41,282 (0%) | 0% | 41.8 | 305,850 | Common Shares |
| Xenon Pharmaceuticals Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 May 2023 | 6,172 | 0 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharmaceuticals Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.85 per share. | 24 May 2023 | 6,172 | 33,880 (0%) | 0% | 9.8 | 60,794 | Common Shares |
| Xenon Pharmaceuticals Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 41.84 per share. | 24 May 2023 | 3,902 | 40,887 (0%) | 0% | 41.8 | 163,260 | Common Shares |
| Xenon Pharmaceuticals Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 41.49 per share. | 24 May 2023 | 1,407 | 31,302 (0%) | 0% | 41.5 | 58,376 | Common Shares |
| Xenon Pharmaceuticals Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 41.84 per share. | 24 May 2023 | 1,171 | 32,709 (0%) | 0% | 41.8 | 48,995 | Common Shares |
| Xenon Pharmaceuticals Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2023 | 380,000 | 380,000 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharmaceuticals Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 400,000 | 400,000 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharmaceuticals Inc | Ian C. Mortimer | Director, PRESIDENT & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2021 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| Xenon Pharmaceuticals Inc | Ian C. Mortimer | PRESIDENT & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2021 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) |